An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma

BACKGROUND: Programmed death ligand 1 (PD-L1) and tumor mutation burden (TMB) have been developed as biomarkers for the treatment of immune checkpoint inhibitors (ICIs). However, some patients who are TMB-high or PD-L1-high remained resistant to ICIs therapy. Therefore, a more clinically applicable...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Chaohu, Tang, Hongzhen, Wang, Wei, Wu, Dongfang, Luo, Haitao, Xu, Libin, Lin, Xue-Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887306/
https://www.ncbi.nlm.nih.gov/pubmed/36733353
http://dx.doi.org/10.3389/fonc.2022.1077477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887306/
https://www.ncbi.nlm.nih.gov/pubmed/36733353
http://dx.doi.org/10.3389/fonc.2022.1077477

Ejemplares similares